Use of Antiretrovirals for HIV Prevention: What Do We Know and What Don’t We Know?
- Jared M. BaetenAffiliated withDepartments of Global Health, Medicine, and Epidemiology, University of Washington Email author
- , Robert GrantAffiliated withGladstone Institutes, University of California, San Francisco
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Pre-exposure prophylaxis (PrEP), in which HIV uninfected persons with ongoing HIV risk use antiretroviral medications as chemoprophylaxis against sexual HIV acquisition, is a promising new HIV prevention strategy. Proof-of-concept that PrEP, as oral or vaginal topical tenofovir-based products, protects against sexual HIV acquisition has been demonstrated in clinical trials conducted among men who have sex with men and heterosexual men and women. The degree of HIV protection in these trials was strongly related to the level of adherence to PrEP. Many questions are yet unanswered – including how to motivate uptake of and sustain adherence to PrEP for HIV prevention, how much PrEP use is enough to achieve HIV protection, and the potential of “next-generation” PrEP agents to improve on this effective technology.
KeywordsAntiretroviral medications Chemoprophylaxis Global epidemic HIV/AIDS HIV prevention Pre-exposure prophylaxis (PrEP) Sexual HIV transmission
- Use of Antiretrovirals for HIV Prevention: What Do We Know and What Don’t We Know?
Current HIV/AIDS Reports
Volume 10, Issue 2 , pp 142-151
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Antiretroviral medications
- Global epidemic
- HIV prevention
- Pre-exposure prophylaxis (PrEP)
- Sexual HIV transmission
- Industry Sectors
- Author Affiliations
- 1. Departments of Global Health, Medicine, and Epidemiology, University of Washington, Box 359927, 325 Ninth Avenue, Seattle, WA, 98104, USA
- 2. Gladstone Institutes, University of California, San Francisco, 1650 Owens Street, San Francisco, CA, 94158, USA